New drug duo tested before surgery for tough bladder cancers
NCT ID NCT02812420
Summary
This early-stage study is testing the safety of a two-drug immunotherapy combination (durvalumab and tremelimumab) given before surgery to patients with aggressive bladder and related urinary tract cancers. The trial is specifically for patients who cannot receive the usual pre-surgery chemotherapy due to health reasons. Researchers will check how patients' immune systems respond and see if the treatment helps shrink or eliminate the cancer before it is surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.